Bye Nicole, Hutt Oliver E, Hinton Tracey M, Acharya Durga P, Waddington Lynne J, Moffat Bradford A, Wright David K, Wang Hong X, Mulet Xavier, Muir Benjamin W
National Trauma Research Institute, Alfred Hospital and Department of Surgery, Monash University , Melbourne 3000, Australia.
Langmuir. 2014 Jul 29;30(29):8898-906. doi: 10.1021/la5007296. Epub 2014 Jul 14.
The purpose of this work was to synthesize and screen, for their effectiveness to act as T1-enhancing magnetic resonance imaging (MRI) contrast agents, a small library of nitroxide lipids incorporated into cubic-phase lipid nanoparticles (cubosomes). The most effective nitroxide lipid was then formulated into lower-toxicity lipid nanoparticles (hexosomes), and effective MR contrast was observed in the aorta and spleen of live rats in vivo. This new class of lower-toxicity lipid nanoparticles allowed for higher relaxivities on the order of those of clinically used gadolinium complexes. The new hexosome formulation presented herein was significantly lower in toxicity and higher in relaxivity than cubosome formulations previously reported by us.
这项工作的目的是合成并筛选一小批掺入立方相脂质纳米颗粒（立方体细胞）中的氮氧化物脂质，以评估它们作为T1增强磁共振成像（MRI）造影剂的有效性。然后将最有效的氮氧化物脂质制成毒性较低的脂质纳米颗粒（六体细胞），并在活体大鼠的主动脉和脾脏中观察到了有效的磁共振造影效果。这类新型的低毒性脂质纳米颗粒的弛豫率更高，与临床使用的钆配合物相当。本文介绍的新型六体细胞制剂的毒性明显低于我们之前报道的立方体细胞制剂，弛豫率则更高。
